NKGN

NKGen Biotech, Inc.

0.84 USD
+0.04 (+5.38%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

NKGen Biotech, Inc. stock is down -44% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 March’s closed higher than February.

About NKGen Biotech, Inc.

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.